Premium
Studies in Menorrhagia: (a) Mefenamic Acid, (b) Endometrial Prostaglandin Concentrations
Author(s) -
Haynes P. J.,
Flint A. P. F.,
Hodgson Helen,
Anderson Anne B. M.,
Dray F.,
Turnbull A. C.
Publication year - 1980
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1002/j.1879-3479.1980.tb00209.x
Subject(s) - medicine , mefenamic acid , prostaglandin , gynecology , pharmacology
Twenty‐two women with unexplained heavy menstrual blood loss (average loss for two cycles of >80 ml) were treated with the prostaglandin synthetase inhibitor mefenamic acid during two consecutive menstruations. There was a significant reduction in menstrual blood loss on mefenamic acid therapy, the median loss being 137 ml before treatment and 76 ml while on treatment. Reduction in menstrual loss was achieved in 20 of the 22 patients but varied from a 2% to 78% reduction. The greater the menstrual loss before treatment, the more it was reduced on mefenamic acid therapy. Endometrial concentrations of prostaglandins E 2 and F 2α in the follicular phase of the cycle were similar whether or not patients had menorrhagia. In the luteal phase, however, 6 of 14 patients with menorrhagia had higher endometrial prostaglandin E 2 and F 2α concentrations than all 13 controls.